Intraocular Pressure
Conditions
Keywords
intraocular pressure, intravitreal
Brief summary
The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. This transient, short-term intraocular pressure elevation (lasting up to 30 minutes) after intravitreal anti-vascular endothelial growth factor therapy has been well describe. The investigators aim to study the prevalence of the sustained intraocular pressure elevation associated with intravitreal injection of anti-vascular endothelial growth factor agents.
Detailed description
Intravitreal injections of anti-vascular endothelial growth factor agents are commonly used to treat a variety of retinal and choroidal neovascular diseases. The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. Although there is one study showed no significant changes in the intraocular pressure many retrospective studies showed the impacts on the intraocular pressure elevation. The investigators aim to prospective evaluate the intraocular pressure change in non-glaucomatous patients receiving an intravitreal anti-vascular endothelial growth factor therapy.
Interventions
DRUGIntravitreal injection (bevacizumab or ranibizumab)
The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
Sponsors
Prince of Songkla University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients scheduled to receive intravitreal injection of anti-vascular endothelial growth factor agent (either bevacizumab or ranibizumab), and * Age of 18-85 year-old, and * Initial intraocular pressure \< 21 mmHg
Exclusion criteria
* Diagnosis of open angle, or * Diagnosis of angle-closure glaucoma, or * Diagnosis of glaucoma suspect (intraocular pressure \> 21 mmHg on 2-consecutive visit and/or cup to disc ratio \> 0.5) , or * Currently receive systemic beta-blocker * Previously received intravitreal injection of anti-vascular endothelial growth factor agent * Previously received intravitreal injection of steroid or gancyclovir * Current use of steroid eye drop * Any ocular surface disease preclude a reliable intraocular pressure measurement
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in intraocular pressure | 6-month after injection | intraocular pressure change at 6-month after injection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of anti-glaucoma used | 6-month | Start anti-glaucoma If there is an increase in intraocular pressure over the target IOP |
Countries
Thailand
Outcome results
None listed